Regeneron Pharmaceuticals' Share-based Compensation rose 5.29% to $237.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 14.15%. This contributed to the annual value of $982.8 million for FY2024, which is 11.05% up from last year.
According to the latest figures from Q3 2025, Regeneron Pharmaceuticals' Share-based Compensation is $237.0 million, which was down 5.84% from $251.7 million recorded in Q2 2025.
Regeneron Pharmaceuticals' 5-year Share-based Compensation high stood at $304.4 million for Q4 2024, and its period low was $130.9 million during Q1 2021.
Its 3-year average for Share-based Compensation is $237.5 million, with a median of $237.0 million in 2025.
As far as peak fluctuations go, Regeneron Pharmaceuticals' Share-based Compensation soared by 55.06% in 2021, and later fell by 3.60% in 2024.
Over the past 5 years, Regeneron Pharmaceuticals' Share-based Compensation (Quarterly) stood at $188.4 million in 2021, then grew by 23.14% to $232.0 million in 2022, then rose by 3.62% to $240.4 million in 2023, then climbed by 26.62% to $304.4 million in 2024, then grew by 5.29% to $237.0 million in 2025.
Its Share-based Compensation stands at $237.0 million for Q3 2025, versus $251.7 million for Q2 2025 and $255.7 million for Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value